Fiera Capital Corp Increases Position in Alnylam Pharmaceuticals, Inc. $ALNY

Fiera Capital Corp raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 93.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 53,804 shares of the biopharmaceutical company’s stock after purchasing an additional 26,061 shares during the period. Fiera Capital Corp’s holdings in Alnylam Pharmaceuticals were worth $24,535,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $30,000. ORG Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $37,000. 92.97% of the stock is owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president owned 59,802 shares of the company’s stock, valued at approximately $18,543,404.16. This represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,578 shares of company stock valued at $12,416,105 in the last 90 days. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALNY. Needham & Company LLC dropped their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Barclays assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target for the company. Finally, Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Stock Down 0.9%

Shares of Alnylam Pharmaceuticals stock opened at $336.19 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The company’s 50 day moving average is $366.89 and its 200 day moving average is $422.44. The company has a market cap of $44.59 billion, a price-to-earnings ratio of 196.60 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.